Skip to main content
Premium Trial:

Request an Annual Quote

Five RNAi-Related Patent Applications Published by the USPTO: Jun 17, 2005

Premium

Title: : RNA Interference-Mediated Inhibition of CXCR4 Gene Expression Using Short Interfering Nucleic Acid

Number: 20050124569

Filed: July 16, 2004

Inventor: Roberto Guerciolini, Sirna Therapeutics

"This invention relates to compounds, compositions, and methods useful for modulating chemokine receptor (CXCR) gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of CXCR gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of CXCR genes such as CXCR4 and CXCR7A."


Title: RNA Interference-Mediated Inhibition of Acetyl-CoA-Carboxylase Gene Expression Using Short Interfering Nucleic Acid

Number: 20050124568

Filed: July 9, 2004

Lead Inventor: Nassim Usman, Sirna Therapeutics

"This invention relates to compounds, compositions, and methods useful for modulating acetyl-CoA carboxylase gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of acetyl-CoA carboxylase gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of acetyl-CoA carboxylase genes."


Title: RNA Interference-Mediated Inhibition of TRPM7 Gene Expression Using Short Interfering Nucleic Acid

Number: 20050124567

Filed: July 1, 2004

Lead Inventor: James McSwiggen, Sirna Therapeutics

"This invention relates to compounds, compositions, and methods useful for modulating TRPM7 gene expression using short interfering nucleic acid molecules," according to the patent application's abstract. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of TRPM7 gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of TRPM7 genes."


Title: RNA Interference-Mediated Inhibition of Myostatin Gene Expression Using Short Interfering Nucleic Acid

Number: 20050124566

Filed: June 28, 2004

Lead Inventor: Howard Robin, Sirna Therapeutics

"This invention relates to compounds, compositions, and methods useful for modulating myostatin (GDF8) gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of myostatin gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of myostatin genes."


Title: Methods of Rapid Detection and Identification of Bioagents Using microRNA

Number: 20050123952

Filed: Sept. 3, 2004

Lead Inventor: Richard Griffey, Ibis Therapeutics

According to the patent application's abstract, the invention comprises "methods for detecting and identifying unknown bioagents, including bacteria, viruses and the like, by a combination of microRNA containing nucleic acid amplification and molecular weight determination using primers which hybridize to conserved sequence regions of microRNA containing nucleic acids derived from a bioagent and which bracket variable sequence regions that uniquely identify the bioagent."

The abstract adds that "the result is a 'base composition signature' or molecular mass which is then matched against a database of base composition signatures or molecular masses, by which the species of the bioagent is identified."